Issue 27 of Multiple Myeloma Research Review Highlights include:  Low dose lenalidomide + dexamethasone in newly diagnosed POEMS syndrome. Loss of heterozygosity indicates homologous repair deficiency in MM. Treatment intensification with SCT + lenalidomide in new MM in CR. Download hereContinue Reading

CRISPR (pronounced “crisper”) and CAR T-cell therapy are genetic technologies that have generated continued excitement during the last several years.  CRISPR is a genome editing tool that allows alteration of a genome.  Compared to other genome editing tools, it is faster, cheaper, and more accurate.  Its applications are numerous, ranging from agriculture to gene therapy....Continue Reading

Previous studies have suggested that the progression of SMM to symptomatic multiple myeloma (MM) may be mediated by the immune system; reinforcing the immune system with a the PVX-410 vaccine may prevent or slow progression to MM. Co-administration with lenalidomide may further enhance an immune response. For this phase 1/2a study, researchers administered 6 doses...Continue Reading

FDA approval is being sought for a once-weekly dosing option of carfilzomib (Kyprolis) for use in combination with dexamethasone as a treatment for patients with relapsed/refractory multiple myeloma. Amgen, the manufacturer of the proteasome inhibitor, announced the submission of a supplemental new drug application (sNDA) seeking this approval today. The application is based on results from the phase...Continue Reading

Over the past 5 years, several therapies have been developed that have proven to be effective for patients with multiple myeloma. The FDA has approved several 3-drug regimens, including the combination of immunomodulatory drugs (IMiDs), a proteasome inhibitor, and dexamethasone, which is now the standard of care in the first-line setting. At this time, there...Continue Reading